Does the media prefer IMCR or AUTL?

In the previous week, Immunocore had 3 more articles in the media than Autolus Therapeutics. MarketBeat recorded 6 mentions for Immunocore and 3 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.72 beat Immunocore's score of 0.18 indicating that Autolus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunocore 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Autolus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AUTL or AVBP?

In the previous week, ArriVent BioPharma had 1 more articles in the media than Autolus Therapeutics. MarketBeat recorded 4 mentions for ArriVent BioPharma and 3 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.72 beat ArriVent BioPharma's score of 0.62 indicating that Autolus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ArriVent BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer HROW or AUTL?

In the previous week, Autolus Therapeutics had 1 more articles in the media than Harrow. MarketBeat recorded 3 mentions for Autolus Therapeutics and 2 mentions for Harrow. Harrow's average media sentiment score of 0.94 beat Autolus Therapeutics' score of 0.72 indicating that Harrow is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Autolus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AUTL or MPLT?

In the previous week, Maplight Therapeutics had 2 more articles in the media than Autolus Therapeutics. MarketBeat recorded 5 mentions for Maplight Therapeutics and 3 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.72 beat Maplight Therapeutics' score of 0.70 indicating that Autolus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maplight Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AUTL or MRVI?

In the previous week, Autolus Therapeutics and Autolus Therapeutics both had 3 articles in the media. Maravai LifeSciences' average media sentiment score of 1.87 beat Autolus Therapeutics' score of 0.72 indicating that Maravai LifeSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maravai LifeSciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Autolus Therapeutics (AUTL) Competitors

$1.42 -0.06 (-3.72%)

As of 12:48 PM Eastern

Compare

AUTL vs. IMCR, AVBP, HROW, MPLT, and MRVI

Should you buy Autolus Therapeutics stock or one of its competitors? MarketBeat compares Autolus Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Autolus Therapeutics include Immunocore (IMCR), ArriVent BioPharma (AVBP), Harrow (HROW), Maplight Therapeutics (MPLT), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical products" industry.

How does Autolus Therapeutics compare to Immunocore?

Immunocore (NASDAQ:IMCR) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Immunocore had 3 more articles in the media than Autolus Therapeutics. MarketBeat recorded 6 mentions for Immunocore and 3 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.72 beat Immunocore's score of 0.18 indicating that Autolus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunocore	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Autolus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunocore has a net margin of -6.68% compared to Autolus Therapeutics' net margin of -311.98%. Immunocore's return on equity of -7.07% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-6.68%	-7.07%	-2.55%
Autolus Therapeutics	-311.98%	-128.59%	-46.25%

84.5% of Immunocore shares are owned by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are owned by institutional investors. 10.1% of Immunocore shares are owned by insiders. Comparatively, 25.7% of Autolus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Immunocore has higher revenue and earnings than Autolus Therapeutics. Immunocore is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$400.02M	4.31	-$35.51M	-$0.55	N/A
Autolus Therapeutics	$75.39M	5.03	-$287.53M	-$1.09	N/A

Immunocore has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market. Comparatively, Autolus Therapeutics has a beta of 2.04, suggesting that its share price is 104% more volatile than the broader market.

Immunocore currently has a consensus price target of $56.71, indicating a potential upside of 67.48%. Autolus Therapeutics has a consensus price target of $8.75, indicating a potential upside of 514.04%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Autolus Therapeutics is more favorable than Immunocore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.40
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Summary

Immunocore and Autolus Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Autolus Therapeutics compare to ArriVent BioPharma?

Autolus Therapeutics (NASDAQ:AUTL) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

Autolus Therapeutics has a beta of 2.04, meaning that its share price is 104% more volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.29, meaning that its share price is 29% more volatile than the broader market.

72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by insiders. Comparatively, 8.6% of ArriVent BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

ArriVent BioPharma has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -311.98%. ArriVent BioPharma's return on equity of -48.98% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-311.98%	-128.59%	-46.25%
ArriVent BioPharma	N/A	-48.98%	-45.44%

Autolus Therapeutics currently has a consensus target price of $8.75, suggesting a potential upside of 514.04%. ArriVent BioPharma has a consensus target price of $44.83, suggesting a potential upside of 36.30%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Autolus Therapeutics is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

ArriVent BioPharma has lower revenue, but higher earnings than Autolus Therapeutics. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$75.39M	5.03	-$287.53M	-$1.09	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

In the previous week, ArriVent BioPharma had 1 more articles in the media than Autolus Therapeutics. MarketBeat recorded 4 mentions for ArriVent BioPharma and 3 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.72 beat ArriVent BioPharma's score of 0.62 indicating that Autolus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ArriVent BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Autolus Therapeutics beats ArriVent BioPharma on 10 of the 16 factors compared between the two stocks.

How does Autolus Therapeutics compare to Harrow?

Harrow (NASDAQ:HROW) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Harrow has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market. Comparatively, Autolus Therapeutics has a beta of 2.04, indicating that its share price is 104% more volatile than the broader market.

Harrow has a net margin of -5.57% compared to Autolus Therapeutics' net margin of -311.98%. Harrow's return on equity of 19.59% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harrow	-5.57%	19.59%	2.26%
Autolus Therapeutics	-311.98%	-128.59%	-46.25%

Harrow has higher revenue and earnings than Autolus Therapeutics. Harrow is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$272.30M	5.70	-$5.14M	-$0.41	N/A
Autolus Therapeutics	$75.39M	5.03	-$287.53M	-$1.09	N/A

Harrow presently has a consensus target price of $69.43, suggesting a potential upside of 66.64%. Autolus Therapeutics has a consensus target price of $8.75, suggesting a potential upside of 514.04%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Autolus Therapeutics is more favorable than Harrow.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

72.8% of Harrow shares are owned by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are owned by institutional investors. 12.8% of Harrow shares are owned by insiders. Comparatively, 25.7% of Autolus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Autolus Therapeutics had 1 more articles in the media than Harrow. MarketBeat recorded 3 mentions for Autolus Therapeutics and 2 mentions for Harrow. Harrow's average media sentiment score of 0.94 beat Autolus Therapeutics' score of 0.72 indicating that Harrow is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harrow	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Autolus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Harrow beats Autolus Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Autolus Therapeutics compare to Maplight Therapeutics?

Autolus Therapeutics (NASDAQ:AUTL) and Maplight Therapeutics (NASDAQ:MPLT) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

72.8% of Autolus Therapeutics shares are owned by institutional investors. 25.7% of Autolus Therapeutics shares are owned by insiders. Comparatively, 3.8% of Maplight Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Maplight Therapeutics has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -311.98%. Maplight Therapeutics' return on equity of 0.00% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-311.98%	-128.59%	-46.25%
Maplight Therapeutics	N/A	N/A	N/A

Autolus Therapeutics presently has a consensus price target of $8.75, indicating a potential upside of 514.04%. Maplight Therapeutics has a consensus price target of $39.10, indicating a potential upside of 4.71%. Given Autolus Therapeutics' higher probable upside, research analysts plainly believe Autolus Therapeutics is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	5 Strong Buy rating(s)	3.13

In the previous week, Maplight Therapeutics had 2 more articles in the media than Autolus Therapeutics. MarketBeat recorded 5 mentions for Maplight Therapeutics and 3 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.72 beat Maplight Therapeutics' score of 0.70 indicating that Autolus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maplight Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Maplight Therapeutics has lower revenue, but higher earnings than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$75.39M	5.03	-$287.53M	-$1.09	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A

Summary

Maplight Therapeutics beats Autolus Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Autolus Therapeutics compare to Maravai LifeSciences?

Autolus Therapeutics (NASDAQ:AUTL) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment.

72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by insiders. Comparatively, 2.5% of Maravai LifeSciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Maravai LifeSciences has a net margin of -51.07% compared to Autolus Therapeutics' net margin of -311.98%. Maravai LifeSciences' return on equity of -17.87% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-311.98%	-128.59%	-46.25%
Maravai LifeSciences	-51.07%	-17.87%	-9.08%

Maravai LifeSciences has higher revenue and earnings than Autolus Therapeutics. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$75.39M	5.03	-$287.53M	-$1.09	N/A
Maravai LifeSciences	$185.74M	9.00	-$130.77M	-$0.71	N/A

In the previous week, Autolus Therapeutics and Autolus Therapeutics both had 3 articles in the media. Maravai LifeSciences' average media sentiment score of 1.87 beat Autolus Therapeutics' score of 0.72 indicating that Maravai LifeSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maravai LifeSciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Autolus Therapeutics currently has a consensus price target of $8.75, indicating a potential upside of 514.04%. Maravai LifeSciences has a consensus price target of $5.50, indicating a potential downside of 15.04%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Autolus Therapeutics is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Autolus Therapeutics has a beta of 2.04, suggesting that its share price is 104% more volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market.

Summary

Autolus Therapeutics and Maravai LifeSciences tied by winning 8 of the 16 factors compared between the two stocks.

Get Autolus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AUTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AUTL vs. The Competition

Export

Metric	Autolus Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$379.28M	$3.65B	$6.75B	$12.52B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-1.31	21.14	26.97	24.40
Price / Sales	5.03	317.89	583.13	118.35
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	2.13	8.56	10.84	6.34
Net Income	-$287.53M	$23.83M	$3.58B	$330.77M
7 Day Performance	-11.49%	-2.97%	-2.03%	-0.83%
1 Month Performance	-8.65%	6.91%	3.35%	-0.25%
1 Year Performance	-46.23%	49.59%	26.71%	20.22%

Autolus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AUTL Autolus Therapeutics	2.9391 of 5 stars	$1.43 -3.7%	$8.75 +514.0%	-40.1%	$379.28M	$75.39M	N/A	330
IMCR Immunocore	3.3557 of 5 stars	$31.94 -1.7%	$56.71 +77.6%	-7.2%	$1.65B	$400.02M	N/A	320	Analyst Downgrade
AVBP ArriVent BioPharma	2.7301 of 5 stars	$34.49 -0.5%	$43.14 +25.1%	+55.5%	$1.61B	N/A	N/A	40
HROW Harrow	4.2903 of 5 stars	$44.93 +5.1%	$69.43 +54.5%	+19.7%	$1.59B	$272.30M	N/A	180
MPLT Maplight Therapeutics	1.6741 of 5 stars	$35.04 -5.5%	$38.80 +10.7%	N/A	$1.58B	N/A	N/A	109

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AUTL) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Autolus Therapeutics (AUTL) Competitors

AUTL vs. IMCR, AVBP, HROW, MPLT, and MRVI

How does Autolus Therapeutics compare to Immunocore?

Summary

How does Autolus Therapeutics compare to ArriVent BioPharma?

Summary

How does Autolus Therapeutics compare to Harrow?

Summary

How does Autolus Therapeutics compare to Maplight Therapeutics?

Summary

How does Autolus Therapeutics compare to Maravai LifeSciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUTL vs. The Competition

Autolus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Autolus Therapeutics (AUTL) Competitors

AUTL vs. IMCR, AVBP, HROW, MPLT, and MRVI

How does Autolus Therapeutics compare to Immunocore?

Does the media prefer IMCR or AUTL?

Is IMCR or AUTL more profitable?

Do institutionals & insiders believe in IMCR or AUTL?

Which has stronger earnings and valuation, IMCR or AUTL?

Which has more risk & volatility, IMCR or AUTL?

Do analysts recommend IMCR or AUTL?

Summary

How does Autolus Therapeutics compare to ArriVent BioPharma?

Which has more volatility & risk, AUTL or AVBP?

Do institutionals and insiders hold more shares of AUTL or AVBP?

Is AUTL or AVBP more profitable?

Do analysts recommend AUTL or AVBP?

Which has preferable valuation and earnings, AUTL or AVBP?

Does the media refer more to AUTL or AVBP?

Summary

How does Autolus Therapeutics compare to Harrow?

Which has more risk and volatility, HROW or AUTL?

Is HROW or AUTL more profitable?

Which has preferable valuation & earnings, HROW or AUTL?

Do analysts prefer HROW or AUTL?

Do institutionals & insiders have more ownership in HROW or AUTL?

Does the media prefer HROW or AUTL?

Summary

How does Autolus Therapeutics compare to Maplight Therapeutics?

Do insiders and institutionals believe in AUTL or MPLT?

Is AUTL or MPLT more profitable?

Do analysts recommend AUTL or MPLT?

Does the media prefer AUTL or MPLT?

Which has preferable earnings & valuation, AUTL or MPLT?

Summary

How does Autolus Therapeutics compare to Maravai LifeSciences?

Do institutionals and insiders hold more shares of AUTL or MRVI?

Is AUTL or MRVI more profitable?

Which has better earnings & valuation, AUTL or MRVI?

Does the media prefer AUTL or MRVI?

Do analysts recommend AUTL or MRVI?

Which has more volatility & risk, AUTL or MRVI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUTL vs. The Competition

Autolus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools